U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937567) titled 'CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors' on Dec. 24, 2024.
Brief Summary: The investigational product used in this study, UCLH801 cells, is a CAR-T cell therapy specifically targeting CDH17. The proposed indication includes CDH17-positive advanced solid tumors, such as but not limited to colorectal cancer, gastric cancer, pancreatic cancer, biliary tract tumors, neuroendocrine tumors, ovarian cancer, and lung cancer. The primary objective of this study is to evaluate the safety and tolerability of UCLH801 cells in patients with CDH17-positive advanced malignant solid tumors. The secondary objectives include assessing...